Personalised medical plan and nutritional monitoring
Area of Obesity
The pharmacological treatment of obesity has advanced significantly in recent years, with the incorporation of new agents that offer greater weight reductions and better safety profile.
GLP-1 receptor agonists (GLP-1-RAs) have demonstrated average weight losses of 10-15%. More recently, tirzepatide, a dual GLP-1 and GIP receptor agonist, has shown weight reductions of close to 20%, approaching results traditionally associated with some bariatric surgery techniques.
These therapies not only act by modulating satiety and appetite at a central level, but also improve metabolic parameters such as glycemia and lipid profile and have shown improvement in comorbidities such as metabolic hepatic disease and obstructive sleep apnea, as well as reduction of cardiovascular risk. In addition, there is a wide field of research with new drugs in development.
Treatment should be maintained on a long-term basis, especially if the patient responds well and has no significant adverse effects. Discontinuing treatment usually leads to weight regain.
Contact us if you need more information or advice on the checkup you need.
Pharmacological treatment objectives
A 5% decrease in body weight is already associated with significant clinical benefits.
Achieving weight loss
≥ 5-10% of initial weight
Improve or resolve
associated comorbidities
Preventing the increase
subsequent weight gain
Improve the
quality of life
Pharmacological management should be personalized considering the profile of comorbidities, preferences and individual tolerance and should be integrated within a multidisciplinary approach, combining it with nutritional intervention, physical activity and psychological support, since obesity is a chronic disease of multifactorial origin that requires a long-term approach.